Sangamo BioSciences Announces Completion Of Enrollment Of Phase 2 Clinical Trial Of ZFP Therapeutic For Diabetic Neuropathy
Dec 6th 2007Drug InformationDiabetes
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that the company has completed enrollment of its randomized, double-blind, repeat-dosing, placebo-controlled, multi-center Phase 2 clinical trial evaluating SB-509, a ZFP Therapeutic(TM) for the treatment of mild to moderate diabetic neuropathy (DN). The company expects to have data from this trial in the second half of 2008. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
